2023 ESC Guidelines for the management of cardiomyopathiesElena Arbelo, Ulf Landmesser, Damien Bonnet et al.|European Heart Journal|2023Cited by 2.3k
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trialIacopo Olivotto, Amos Katz, Artur Oręziak et al.|The Lancet|2020Cited by 1.2k
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial DiseasesPablo García‐Pavía, Aleš Linhart, Claudio Rapezzi et al.|European Heart Journal|2021Cited by 1.1k
Glycogen Storage Diseases Presenting as Hypertrophic CardiomyopathyMichael Arad, Jonathan G. Seidman, Barry J. Maron et al.|New England Journal of Medicine|2005Cited by 646
Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial DiseasesPhilippe Charron, Luigi Tavazzi, Michael Arad et al.|European Heart Journal|2010Cited by 485